血清鳞状细胞癌抗原在宫颈鳞状细胞癌临床管理中的进展

血清鳞状细胞癌抗原(SCC-Ag)是宫颈鳞状细胞癌(CSCC)最常用的肿瘤标志物,是CSCC的预后预测指标;SCC-Ag与早期CSCC的术后临床病理高危因素相关,与术后辅助治疗风险相关,SCC-Ag的补充有助于建立更完善的危险因素预测模型,指导术后辅助治疗;SCC-Ag水平在宫颈癌治疗过程中下降,逐渐正常化,可以籍以判断疗效、预测复发;在随访过程中,SCC-Ag的升高先于临床复发,结合PET-CT检查可有效地评估病情、判断复发。SCCAg在CSCC的全程管理中发挥重要作用,可以作为个体化和精细化风险预评估的指标。

Progress of Squamous Cell Carcinoma Antigen in Clinical Management of Cervical Squamous Cell Carcinoma

Serum squamous cell carcinoma antigen(SCC-Ag) is the most commonly used tumor marker as a prognostic indicator for cervical squamous cell carcinoma. It is correlated with postoperative clinical and pathological risk of early cervical squamous cell carcinoma,and also correlated with risk of postoperative adjuvant therapy. The combination of SCC-Ag detection and clinical and pathological risk factors can be used to establish a more complete risk factor predictive model for subsequent therapy. SCC-Ag levels are decreases during the treatment,and return to normal levels after effective treatment,so it can be used to monitor the therapeutic response and to predict recurrence. During the follow-up,SCC-Ag level often rises before clinical relapse,SCC-Ag level combined with PET-CT examination can effectively assess the condition and detect recurrence.Detection of SCC-Ag may play an important role in the management of cervical squamous cell carcinoma and can be used as an indicator for individualized and refined risk evaluation before treatment.